Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 11/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | PNMT | P11086 | 3/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8240599 | 0.80 | PDK2 (0.40) | BACE1ADORA2ACYP11B1CYP11B2PDK2 | |
| Hydrochloric Acid SCHEMBL5002152 | 0.79 | PDK2 (0.40) | BACE1ADORA2ACYP11B1CYP11B2PDK2 | |
| SCHEMBL14036901 | 0.73 | — | — | |
| SCHEMBL14036742 | 0.73 | PDK2 (0.42) | PDK2 | |
| SCHEMBL5001690 | 0.70 | BACE1 (0.38) | BACE1ADORA2APDK2 | |
| SCHEMBL5002063 | 0.66 | BACE1 (0.43) | BACE1 | |
| SCHEMBL20080425 | 0.59 | PDK2 (0.51) | PDK2 | |
| SCHEMBL23782830 | 0.59 | HTR2A (0.38) | CYP11B1CYP11B2PDK2PNMT | |
| SCHEMBL14010655 | 0.59 | NOS3 (0.38) | BACE1 | |
| SCHEMBL16014964 | 0.58 | KDM1A (0.42) | BACE1PDK2PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293709-A1 | Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293709-A1 | Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies | PSEN2, APP, PSEN1 | BACE1 4/4885ADORA2A 500/4885CYP11B1 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.